n.a. (ONXX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

Mergers Don't Lift Stocks

Mergers Don't Lift Stocks

Mergers from Amgen, Onyx and TMS International aren't enough to persuade stocks to move higher. Qihoo investors are happy with its earnings.

Good Morning!

It's an honor to fill in for the one and only Doug Kass here on the Diary. Here's what's happening: Futures are offered slightly lower in early trading. Metals are consolidating gains after last week's torrid rally. Onyx Pharmaceutical (ONXX) agreed...

Retail Gloom Persists with Kohl's

Retail Gloom Persists with Kohl's

Department store chain Kohl's reports second-quarter results that narrowly misses analysts' expectations.

Onyx Pharmaceuticals downgraded at BMO

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Cramer: Celgene Is a Buy as Biotech Deals Heat-up

Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.

Onyx Pharmaceuticals downgraded at Baird

Playing the Biotechs

There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...

More Healthcare Deals On The Way

More Healthcare Deals On The Way

Expect hospital and biotech deals to dominate during the second half of 2013, says Gerald Adolph, Sr. Partner at Booz & Company.

Fed Up With the Parlor Games

Thanks to handwringing about macro issues, I missed one of the hottest IPOs in recent memory.

The Next Wave of Money

Once the sidelined money realizes their stocks have done better than their bonds, they'll come back in.

Pfizer Deal Sweetens Onyx Pot

Pfizer Deal Sweetens Onyx Pot

Onyx's deal with Pfizer will be a sweetener as bidding for the biotech gets more intense, says Adam Feuerstein, senior columnist at TheStreet.

We've Got a Real Blind Spot

We endure the negatives and we obscure the positives.

Onyx Rejects Amgen's Takeover Bid

Onyx Rejects Amgen's Takeover Bid

Onyx Pharmaceuticals says no to a takeover bid from biotech company Amgen. TheStreet's Brittany Umar has details in Monday's Ahead of the Ticker.

Stocks Kick Off July in the Green

Stocks Kick Off July in the Green

Stocks get July started in positive territory as Onyx rejects Amgen, Apple trademarks the iWatch and Nokia takes ownership of its networks.

The Baffling Disappearance of M&A

What are these putative buyers scared of?

Earnings Roundup

Here is my compilation of last night's profit reports. 24 beats: W&T Offshore (WTI) Oasis Petroleum (OAS) Marathon Oil (MRO) Huntington Ingalls Industries (HII) Cognizant Technology Solutions (CTSH) Disney (DIS) Electronic Arts (EA) Regency Centers ...

Even Further Divorced From Logic

Even Further Divorced From Logic

The S&P looks set to hit another lofty level, even as it remains unsupported by fundamentals.

Off the Charts

Off the Charts

Book profits, don't chase strength.

Consider Playing Catch-Up Via Biotech

Deep-in-the-money call options on these five names could provide a healthy return.

Market Takes Aim at Historic Highs Once Again

Market Takes Aim at Historic Highs Once Again

Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.

Off the Charts

Off the Charts

Upward momentum is lagging.

Off the Charts

Off the Charts

Continue to stay flexible until we get more clarity. 

Ready to Roll With ONYX

Ready to Roll With ONYX

Feeling good about the biotechs.